Opendata, web and dolomites

Obsidian SIGNED

Obsidian Anastomotic SafeGuard – A powerful and efficient tissue sealant method for reducing the anastomotic leak rate in colorectal surgery

Total Cost €


EC-Contrib. €






 Obsidian project word cloud

Explore the words cloud of the Obsidian project. It provides you a very rough idea of what is the project "Obsidian" about.

million    contains    opportunity    grow    colorectal    transmission    2018    thrombin    prepation    total    post    leak    gastrointestinal    faces    solution    risk    added    sealing    treating    minutes    ibd    79m    diseases    profits    300    cancer    anastomotic    ends    rates    preparation    first    sme    bovine    full    reduces    worldwide    obsidian    decrease    market    blood    reg    platelet    intestinal    fast    business    patients    wound    3rd    ibds    anastomosis    rate    approx    asg    resection    natural    needing    instrument    grant    huge    14    sealant    inflammatory    clinical    24    autologous    eliminated    biocompatibility    conduct    42m    p1    selant    applicable    solid    issue    fibrin    2b    revenue    leaks    offers    components    disease    setting    asia    leveraging    97m    stimulation    gluing    commercialization    oceania    tissue    time    significantly    healing    bowel    completing    considering    19    stump    astonishing    site    adding    vivostat    surgery    societal    procedure   

Project "Obsidian" data sheet

The following table provides information about the project.

Vivostat A/S 

Organization address
address: BORUPVANG 2
postcode: 3450
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-04-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    Vivostat A/S DK (ALLEROD) coordinator 50˙000.00


 Project objective

Obsidian ASG® is the first – and only - autologous fibrin tissue sealant applicable for gastrointestinal anastomosis, that will significantly decrease the anastomotic leak rate, following gastrointestinal resection when treating Inflammatory Bowel Diseases (IBDs) or Colorectal Cancer. The current number of anastomotic leak rates is a large societal issue, as studies show rates as high as 19%. Considering that approx. 1.8 million new cases of colorectal cancer will occur worldwide in 2018 (being the 3rd most common cancer type), the number of leaks is astonishing – and this is only for colorectal cancer. Adding the number of IBD patients needing a resection, Obsidian ASG® faces a market potential of 0.79M patients just in Europe, Asia and Oceania every year. Leveraging on this market opportunity, Obsidian ASG® contains all the components needed for on-site prepation and application of an autologous platelet rich fibrin selant – a preparation that can be completed in less than 30 minutes. As the only product in the market, Obsidian ASG® offers 1) a long-term cost-effective procedure for gluing and sealing intestinal stump-ends; 2) A fast and natural stimulation of wound healing that significantly reduces the anastomotic leak rates; and 3) Full biocompatibility, eliminated risk of blood disease transmission and no thrombin or bovine components added to the blood or Obsidian ASG® solution at any time during the process. Yet, to reach market commercialization, we need to conduct a clinical study of Obsidian ASG® with 300 colorectal pre-surgery patients. The SME P1 grant will be crucial for completing the design of the clinical study as well as setting up key partnerships for the proposed clinical study (to be set up in a SME-2b Instrument Project). As such, the SME-Instrument represents a huge opportunity for Vivostat A/S, as we expect to grow a solid business case year 1-5 post-project, with a total revenue of €24.97M and profits of €14.42M.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OBSIDIAN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OBSIDIAN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More